Ireland
--:--IST
Recruiting Not applicable

Impact of Single- Versus Double-layer Hysterotomy Closure on Cesarean Niche Development: a Randomized Controlled Trial

NCT06308172 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2021-12-01
Last updated
2024-03-13

Condition(s) studied

Cesarean Section; DehiscenceUterine BleedingUterus; ScarUterus AbnormalCesarean Section Complications

Investigational drug(s) / intervention(s)

Hysterotomy closure

Hysterotomy closure: Hysterotomy closure is done in either one of two ways. Single layer closure consists in a single layer, unlocked suture. Double layer closure consists in a double layer, unlocked suture.

Study summary

The objective of this randomized monocentric study is to assess potential variations in the incidence and severity of isthmocele morbidity among women undergoing cesarean section with either single or double-layer closure of the hysterotomy. Our primary outcome aims to investigate whether there is a reduction in the median duration of intermenstrual spotting in patients belonging to the two respective closure groups

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * nulliparous * singleton * age 18-45 * spontaneous pregnancy or autologous assisted fertilization * gestational age 38-40 weeks * elective C-section * informed consent Exclusion Criteria: * coagulopathy * autoimmune diseases * gestational diabetes * anticoagulant therapy * immunosuppressive therapy * endometriosis * uterine fibromatosis * spontaneous labour * connective tissue diseases

Primary outcome measure(s)

  • Intermenstrual bleeding reduction (days) — 6 months
    The primary outcome of the study is to evaluate weather there is a reduction of intermenstrual bleeding in the six months after cesarean section among the two groups of patients.

Trial sites (1)

FacilityCityRegionStatus
Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico di Milano Milan Mi Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06308172 on ClinicalTrials.gov ↗ ← All trials in Italy